Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review

被引:7
|
作者
Aldinc, Emre [1 ]
Campbell, Courtney [2 ]
Gustafsson, Finn [3 ]
Beveridge, Abigail [4 ]
Macey, Richard [4 ]
Marr, Laura [4 ]
Summers, Catherine [1 ]
Zhang, Dafang [5 ]
机构
[1] Alnylam Pharmaceut, Cambridge, MA 02115 USA
[2] Baylor Scott & White Heart & Vasc Hosp, Dallas, TX USA
[3] Univ Copenhagen, Rigshopsitalet, Copenhagen, Denmark
[4] Adelphi Values PROVETM, Bollington, England
[5] Brigham & Womens Hosp, Boston, MA USA
关键词
CARPAL-TUNNEL-SYNDROME; POLYNEUROPATHY TTR-FAP; CARDIAC AMYLOIDOSIS; LIGAMENTUM-FLAVUM; COMMON-CAUSE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; HEART-FAILURE; DEPOSITION; MUTATIONS;
D O I
10.1186/s12891-023-06853-5
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
BackgroundHereditary and wild-type transthyretin-mediated (ATTRv and ATTRwt) amyloidoses result from the misfolding of transthyretin and aggregation of amyloid plaques in multiple organ systems. Diagnosis of ATTR amyloidosis is often delayed due to its heterogenous and non-specific presentation. This review investigates the association of musculoskeletal (MSK) manifestations with ATTR amyloidosis and the delay from the onset of these manifestations to the diagnosis of ATTR amyloidosis.MethodsThis systematic review utilized Medline and EMBASE databases. Search criteria were outlined using a pre-specified patient, intervention, comparator, outcome, time, study (PICOTS) criteria and included: amyloidosis, ATTR, and MSK manifestations. Publication quality was assessed utilizing Joanna Briggs Institute (JBI) critical appraisal checklists.The search initially identified 7,139 publications, 164 of which were included. PICOTS criteria led to the inclusion of epidemiology, clinical burden and practice, pathophysiology, and temporality of MSK manifestations associated with ATTR amyloidosis. 163 publications reported on ATTR amyloidosis and MSK manifestations, and 13 publications reported on the delay in ATTR amyloidosis diagnosis following the onset of MSK manifestations.MethodsThis systematic review utilized Medline and EMBASE databases. Search criteria were outlined using a pre-specified patient, intervention, comparator, outcome, time, study (PICOTS) criteria and included: amyloidosis, ATTR, and MSK manifestations. Publication quality was assessed utilizing Joanna Briggs Institute (JBI) critical appraisal checklists.The search initially identified 7,139 publications, 164 of which were included. PICOTS criteria led to the inclusion of epidemiology, clinical burden and practice, pathophysiology, and temporality of MSK manifestations associated with ATTR amyloidosis. 163 publications reported on ATTR amyloidosis and MSK manifestations, and 13 publications reported on the delay in ATTR amyloidosis diagnosis following the onset of MSK manifestations.ResultsThe MSK manifestation most frequently associated with ATTR amyloidosis was carpal tunnel syndrome (CTS); spinal stenosis (SS) and osteoarthritis (OA), among others, were also identified. The exact prevalence of different MSK manifestations in patients with ATTR amyloidosis remains unclear, as a broad range of prevalence estimates were reported. Moreover, the reported prevalence of MSK manifestations showed no clear trend or distinction in association between ATTRv and ATTRwt amyloidosis.MSK manifestations precede the diagnosis of ATTR amyloidosis by years, and there was substantial variation in the reported delay to ATTR amyloidosis diagnosis. Reports do suggest a longer diagnostic delay in patients with ATTRv amyloidosis, with 2 to 12 years delay in ATTRv versus 1.3 to 1.9 years delay in ATTRwt amyloidosis.ResultsThe MSK manifestation most frequently associated with ATTR amyloidosis was carpal tunnel syndrome (CTS); spinal stenosis (SS) and osteoarthritis (OA), among others, were also identified. The exact prevalence of different MSK manifestations in patients with ATTR amyloidosis remains unclear, as a broad range of prevalence estimates were reported. Moreover, the reported prevalence of MSK manifestations showed no clear trend or distinction in association between ATTRv and ATTRwt amyloidosis.MSK manifestations precede the diagnosis of ATTR amyloidosis by years, and there was substantial variation in the reported delay to ATTR amyloidosis diagnosis. Reports do suggest a longer diagnostic delay in patients with ATTRv amyloidosis, with 2 to 12 years delay in ATTRv versus 1.3 to 1.9 years delay in ATTRwt amyloidosis.ConclusionThese findings suggest that orthopedic surgeons may play a role in the early diagnosis of and treatment referrals for ATTR amyloidosis. Detection of MSK manifestations may enable earlier diagnosis and administration of effective treatments before disease progression occurs.
引用
收藏
页数:37
相关论文
共 50 条
  • [21] Cardiovascular burden prior to diagnosis of hereditary transthyretin-mediated amyloidosis
    Llonch, M. V.
    Ortiz-Perez, J. T.
    Reddy, S. R.
    Chang, E.
    Tarbox, M. H. Marian
    Pollock, M. R.
    Nativi-Nicolau, J.
    Fine, N. M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 173 - 174
  • [22] Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis
    Kristen, Arnt, V
    Ajroud-Driss, Senda
    Conceicao, Isabel
    Gorevic, Peter
    Kyriakides, Theodoros
    Obici, Laura
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (01) : 5 - 24
  • [23] Hereditary transthyretin-mediated amyloidosis masquerading as diabetic neuropathy and lumbar radiculopathy
    Horiuchi, Kohei
    Hortelano, Chiara
    Nikfar, Reza
    Fogel, Joyce
    BMJ CASE REPORTS, 2024, 17 (09)
  • [24] The V122I Mutation in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy
    Parker, Margaret M.
    Damrauer, Scott M.
    Rader, Daniel J.
    Ticau, Simina
    Erbe, David
    Hinkle, Gregory
    Nioi, Paul
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S110 - S110
  • [25] The V122I Mutation in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy
    Nioi, Paul
    Parker, Meg M.
    Damrauer, Scott M.
    Rader, Daniel J.
    Ticau, Simina
    Erbe, David
    Hinkle, Greg
    NEUROLOGY, 2020, 94 (15)
  • [26] Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
    Cruz, Marcia Waddington
    CLINICAL AUTONOMIC RESEARCH, 2019, 29 (Suppl 1) : 19 - 24
  • [27] ALN-TTR, an RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis
    Alvarez, R.
    Borland, T.
    Chen, Q.
    Milstein, S.
    Nguyen, T.
    Hinkle, G.
    Kuchimanchi, S.
    Costigan, J.
    Ristoiu, V.
    Wang, G.
    Cole, G.
    Dorkin, R.
    Akinc, A.
    Nechev, L.
    Kosovrasti, V.
    Tchangov, L.
    Tracy, M.
    Jeffs, L.
    MacLachlan, I.
    Lutwyche, P.
    Martins, D.
    Costelha, S.
    Saraiva, M. J.
    Sah, D. W. Y.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2010, 17 : 51 - 52
  • [28] Two novel mutations associated with transthyretin type amyloidosis (ATTR)
    Théberge, R
    Connors, L
    Skinner, M
    Skare, J
    Falk, R
    Costello, CE
    AMYLOID AND AMYLOIDOSIS 1998, 1999, : 300 - 302
  • [29] The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy
    Parker, Margaret M.
    Damrauer, Scott M.
    Tcheandjieu, Catherine
    Erbe, David
    Aldinc, Emre
    Hawkins, Philip N.
    Gillmore, Julian
    Hull, Leland E.
    Lynch, Julie A.
    Joseph, Jacob
    Ticau, Simina
    Flynn-Carroll, Alexander O.
    Deaton, Aimee M.
    Ward, Lucas D.
    Assimes, Themistocles L.
    Tsao, Philip S.
    Chang, Kyong-Mi
    Rader, Daniel J.
    Fitzgerald, Kevin
    Vaishnaw, Akshay K.
    Hinkle, Gregory
    Nioi, Paul
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S96 - S96
  • [30] Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
    Márcia Waddington Cruz
    Clinical Autonomic Research, 2019, 29 : 19 - 24